Charles Ross Schmidtlein, PhD

Charles Ross Schmidtlein, PhD

Charles Ross Schmidtlein, PhD

I am an assistant attending physicist in the Nuclear Medicine Physics section of the Department of Medical Physics. I provide support for research studies on a dedicated PET and CT imaging machine.

I am interested in finding new ways to use information obtained with PET/CT imaging in radiation oncology. To accomplish this, I am developing advanced quantitative PET metrics to aid in treatment prognosis. I am also working to produce advanced image reconstruction schemes and use computer-aided machine learning to improve diagnostic sensitivity, diagnostic accuracy, and physician workflow.

In addition, I am studying dual-energy CT material decomposition to improve the sensitivity of CT scans in the early detection of metastatic disease and to better predict disease progression and treatment response.

I am active in two task groups of the American Association of Physicists in Medicine, TG-126 (Quality Assurance in PET) and TG-211 (Segmentation in PET for Radiation Oncology).


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Charles Ross Schmidtlein discloses the following relationships and financial interests:

  • Tesla, Inc.
    Ownership / Equity Interests

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures